<p>BriaCell Therapeutics Corp. announced that patient enrollment in its pivotal Phase 3 clinical study evaluating Bria-IMT™, in combination with an immune checkpoint inhibitor, for advanced metastatic breast cancer has exceeded expectations. Over 230 patients have been screened and more than 160 patients enrolled to date. The study is being conducted under FDA Fast Track designation. BriaCell anticipates a topline interim data readout in the first half of 2026, pending the occurrence of 144 patient events. No trial results have been presented yet. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9599028) on December 09, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

BCTX

<p>BriaCell Therapeutics Corp. has surpassed enrollment targets in its Phase 3 trial for Bria-IMT™ combined with an immune checkpoint inhibitor for metastatic breast cancer. Over 230 patients have been screened, with more than 160 enrolled. The trial, under FDA Fast Track, expects interim data by mid-2026 after 144 patient events. No results are available yet.</p>

BriaCell Therapeutics Exceeds Enrollment Targets in Pivotal Phase 3 Metastatic Breast Cancer Trial